Journal: Journal of cardiovascular pharmacology
Article Title: Chronic sarpogrelate treatment reveals 5-HT7 receptor in the serotonergic inhibition of the rat vagal bradycardia.
PMID/MRN: 27676327
Publication Date: 2016-Sep-20
Abstract:
5-hydroxytryptamine (5-HT) modulates the cardiac parasympathetic neurotransmission, inhibiting the bradyarrhythmia by 5-HT2 receptor activation. We aimed to determine whether the chronic selective 5-HT2 blockade (sarpogrelate) could modify the serotonergic modulation on vagal cardiac outflow in pithed rat. Bradycardic responses in rats treated with sarpogrelate (30 mg/kg.day; p.o.) were obtained by electrical stimulation of the vagal fibers (3, 6, and 9 Hz) or i.v. injections of acetylcholine (ACh; 1, 5, and 10 ?g/kg). 5-HT7 receptor expression was quantified by Western blot in vagus nerve and right atrium. The i.v. administration of 5-HT (10-200 ?g/kg) dose-dependently decreased vagally-induced bradycardia and agonists 5-CT (5-HT1/7), 8-OH-DPAT (5-HT1A) or AS-19 (5-HT7) (50 ?g/kg each) mimicked the 5-HT-induced inhibitory effect. Neither agonists CGS-12066B (5-HT1B), L-694,247 (5-HT1D) nor 1-phenylbiguanide (5-HT3) modified the electrically-induced bradycardic responses. Moreover, SB-258719 (5-HT7 antagonist) abolished the 5-HT-, 5-CT-, 8-OH-DPAT- and AS-19-induced bradycardia inhibition, 5-HT or AS-19 did not modify the bradycardia induced by i.v. ACh, and 5-HT7 receptor was expressed in both the vagus nerve and the right atrium. Our outcomes suggest that blocking chronically 5-HT2 receptors modifies the serotonergic influence on cardiac vagal neurotransmission exhibiting 5-HT as an exclusively inhibitory agent via prejunctional 5-HT7 receptor.